SHENZHEN, China, Nov. 22, 2024 /PRNewswire/ -- The 19th Annual Meeting of the International Conference on Genomics (ICG-19) officially opened at BGI Group's Global Headquarters in Shenzhen. This annual event brings together over 100 leaders in the field of genomics from the U.S., UK, Denmark, Australia, Singapore, and China amongst others to discuss the latest advancements in global life sciences. Continue Reading Professor Huanming Yang, Co-Founder of BGI Group, delivered a keynote address on m

KNOXVILLE, Tenn., Nov. 22, 2024 /PRNewswire/ -- The Board of Directors of Trinity Health Foundation of East Tennessee announced today a significant leadership transition. After 13 years of dedicated service, President H. Lee Martin, Ph.D., will retire, leaving a legacy of impactful leadership and innovation. Effective January 1, 2025, Lynn Metler will assume the role of President and Executive Director, bringing her own passion and expertise to the foundation's mission of cultivating healthy an

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sel

BERWYN, Pa.--( BUSINESS WIRE )-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immedi

SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024 DENVER, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the two leading independent institutional advisory firms, Institutional Shareholder Services (ISS) and Glass

DUBLIN--( BUSINESS WIRE )--The "Pain Management Devices - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global market for Pain Management Devices is estimated at US$5.1 billion in 2024 and is anticipated to post a CAGR of 8.4% during the 2024-2030 analysis period and stand at a projected US$8.3 billion by 2030. This global report on Pain Management Devices analyzes the market based on type, application, and end-users. In addition to providing profiles

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase up to 5,600,000 shares of Common Stock, and, in lieu t

LANGHORNE, Pa.--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Presentation Details Title: “ Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte's acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in patients with end stage renal disease at the 51st Annual Symposium on Vascular and Endovascula

Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remission at Week 12 and met all secondary endpoints in adults with moderately to severely active UC SPRING HOUSE, Pa., Nov. 22, 2024 /PRNewswi